🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Lymphoma Classifications ICC and WHO: How to Develop a Future Unified Taxonomy | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

A new NCI study shows the ViPOR regimen, a non-chemotherapy treatment, is helping more B-cell lymphoma patients achieve full remission. Dr. Christopher Melani @NCIResearchCtr shares more about this breakthrough: spr.ly/6016lgS3C #CancerResearch #PrecisionMedicine

Thanks for the shoutout Dr. Kimryn Rathmell!! Amazing to see this regimen developed by researchers @NCICCR_Lymphoma changing the lives of our #lymphoma patients

Excited to share 2 year follow-up of SWOG Cancer Research Network S1826: Nivolumab+AVD vs. BV-AVD in Advanced-Stage Classic Hodgkin Lymphoma NEJM Wilmot Cancer Institute nejm.org/doi/full/10.10…

ViPOR regimen in MCL #ASH24 Christopher Melani: - 36 pts (16 R/R), 32% TP53mut, med LOT 3 - R2PD ven dose 400 mg, no TLS, 89% completed all 6 cycles - CR 100% (!!!) - 2-yr PFS: 1L 95%; R/R 75%; 2-yr TTP 100% in TP53mut Also uMRD in 97%! Looking forward to more details on TP53mut. #lymsm

Thanks for the shout out Ajay Major, MD, MBA !! We too are very encouraged by the safety and efficacy of ViPOR in MCL, including high-risk blastoid and TP53m pts. Other big difference is limited duration of 18w without maintenance 👍🏻

Thanks for sharing Ajay Major, MD, MBA …High CR rate and durable PFS in non-GCB as you mention and looks even better in true ABC by RNA-seq. We expanded in non-GCB to see if the CR rate and PFS is significantly better than ViPOR alone…stay tuned!!

Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity | PNAS pnas.org/doi/10.1073/pn… Read the background story of how the VIPOR drugs were discovered to have synergy in LBCL.

Beautiful sunrise to kick off day 1 of #ASH2024. Looking forward to a very educational and productive meeting!

Time-limited VIPOR MCL Christopher Melani #ASH24 - 37 pts, 20 untreated, 34% whole cohort TP53mut - significant hypokalemia (27% G3!), diarrhea, rash - CR: 94% R/R, 100% untreated (!!!), 92% TP53mut - 2-yr TTP 95% 1L, 92% R/R Great data, especially TP53mut-enriched R/R cohort. #lymsm

Christopher Melani MRD dynamics attached. 13% progressed after EOT with MRD lead time of 2.3 months. #ASH24 #lymsm

Great news! I predict the tip of the iceberg for these tests. foresight-dx.com/press_releases…

Helpful review on ctDNA in lymphoma from Mark Roschewski et al just out in JAMA Oncology David Russler-Germain, MD/PhD Ash Alizadeh, MD/PhD 🇺🇸 #lymsm #lymphoma Hua-Jay (Jeff) Cherng JAMA JAMA Network

Many thanks to Lymphoma Research Foundation for the opportunity to present data from our National Cancer Institute study of ViPOR in mantle cell #lymphoma! Great meeting with great discussion from leaders in the field!

Much deserved award to a leader in the field of mantle cell #lymphoma……BRAVO Martin 👏Lymphoma Research Foundation

Results from our Phase III ECHO trial of acalabrutinib + BR vs placebo + BR in untreated MCL patients ≥ 65-y.o. showed PFS was substantially improved in the acalabrutinib arm (66.4 vs 49.6 mo., p = 0.016). Toxicity in both arms was manageable. tinyurl.com/ECHO-ABR

Such a thrill to watch Elaine Jaffe receive the Henry Kaplan award at #ICML2025! Well deserved indeed and an honor to be able to review our #lymphoma cases weekly with her under the microscope National Cancer Institute 👏🏻👏🏻👏🏻

#ClinicalTrial EA4231, led by Christopher Melani of National Cancer Institute, is testing the effectiveness of a combination #TargetedTherapy for patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment. For more info: bit.ly/EA4231 cc: The Leukemia & Lymphoma Society, Lymphoma Hub

Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: bit.ly/EA4231 cc: Christopher Melani, National Cancer Institute, UVA Cancer Center

Excited to validate our single-center National Cancer Institute findings in this multi-center phase II study in additional patients with #lymphoma. Please consider referring patients or opening at your site if interested.